The US Court of Appeals for the Federal Circuit held that the disclosure of an added function in the specification of a ...
Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. §112(a). The USPTO routinely rejects claims as ...